REG - IQ-AI Limited - IB Software Enhances Clinical Decision-Making

IQ-AIAnnouncement

17/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240517:nRSQ8182Oa&default-theme=true

RNS Number : 8182O  IQ-AI Limited  17 May 2024

May 17, 2024

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Imaging Biometrics Software Enhances Clinical Decision-Making at Insel Gruppe
AG

 

Imaging Biometrics (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd
(LSE: IQAI), announces the successful deployment of its state-of-the-art
software at Insel Gruppe AG in Bern, Switzerland. This installation was
facilitated through Bayer's Calantic™ platform on which IB's exclusive
algorithms are made available under a partnership agreement.

 

Clinicians at Insel Gruppe AG are now equipped with IB's quantitative imaging
solutions, renowned for their precision and reliability in aiding critical
clinical decisions. The technology is especially beneficial to
neuroradiologists, oncologists, and surgeons, providing them with enhanced
capabilities to determine the best course of action for their patients swiftly
and effectively.

 

Dr. Arsany Hakim, MD, Head of Brain Tumor Imaging at the Institute of
Diagnostic and Interventional Neuroradiology, stated, "The incorporation of
IB's software into our clinical workflow marks a significant step towards the
standardization of advanced imaging, enhancing both clinical workflow and
patient care. We are eager to utilize the capabilities offered by IB's
solutions in our team to enhance lesion detection and to advance patient
monitoring process, ultimately to improve patient outcomes".

 

Echoing this sentiment, Prof. Roland Wiest, MD, Deputy Director of
Neuroradiology at Insel Gruppe AG, commented, "The adoption of IB's advanced
imaging is expected to be a game-changer in our patient care strategy. We
foresee an immediate enhancement in our ability to tailor treatments to
individual needs."

"We are thrilled to witness the integration of our Calantic partner, Imaging
Biometrics, into the everyday clinical workflow at Insel Gruppe AG, where it
stands poised to provide invaluable support to radiologists and their teams,"
said Lucia Fernandez Lopez, Head of Digital Solutions Business EMEA, Radiology
at Bayer. "With its precise imaging tools, the platform empowers enhanced
diagnostics and treatment planning, fostering efficiency in image analysis
while offering advanced capabilities for biomarker quantification. These
advantages collectively elevate clinical decision-making, ultimately
optimizing patient care within the radiology practice."

 

Michael Schmainda, CEO of Imaging Biometrics, reflected on the significance of
this collaboration: "The installation at Insel Gruppe AG allows them full
access to our comprehensive suite of applications. We are excited about this
collaboration and are committed to supporting Insel Gruppe AG as they set new
standards in patient care."

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 

 IQ-AI Ltd

 Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

 

 

About Insel Gruppe AG

Insel Gruppe AG, one of the longest-running university hospitals in Europe,
was founded in 1354 and has since become a leading medical institution in
Europe, playing a pivotal role in medical education and training. Housing 8
MRI scanners and conducting over 23,000 MRI scans annually, the University
Institute of Diagnostic and Interventional Neuroradiology at Insel Gruppe AG
stands as the largest neuroradiology department in Switzerland. The department
is equipped with state-of-the-art technology, including high-field MRI, and is
nationally and internationally recognized for its clinical excellence and
contributions to the field.

 

In collaboration with the departments of Neurosurgery, Clinical Oncology,
Radiation Therapy, Pathology, and Neurology, the Brain Tumor Center in Bern is
renowned across Switzerland. It offers advanced diagnostic services and
personalized patient management.

 

About Imaging Biometrics® LLC
IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on
delivering quantitative imaging platforms and therapeutics that transform how
clinicians diagnose and treat patients more efficiently and effectively. For
more information about Imaging Biometrics, visit the company's website at
www.imagingbiometrics.com (http://www.imagingbiometrics.com/) . Follow IB on
Twitter, @IQAI_IB.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDGPUUWAUPCPUQ